Aprea Therapeutics
Update in progressAPRE (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on synthetic lethality–based cancer therapies that target DNA damage response pathways. Its lead candidates are APR‑1051, an orally bioavailable WEE1 inhibitor in a Phase 1 trial for biomarker-defined advanced solid tumors, and ATRN‑119, an ATR inhibitor in Phase 1/2a for solid tumors. The company is based in Doylestown, Pennsylvania.
Company score
- Sentiment
- 0.23
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.10
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Oren Gilad Ph.D.
- Employees8
- Websiteaprea.com
Identifiers
- ISINUS03836J1025
- FIGIBBG00Q6Q3K37
- CUSIP03836J102
- CIK0001781983